Übersetzung für "Eosinophil count" in Deutsch

The rate of exacerbations in the placebo arm increased with increasing baseline blood eosinophil count.

Table 3 shows the results of a combined analysis of the two exacerbation studies (MEA112997 and MEA115588) by baseline blood eosinophil count.

The eosinophil count increased from 2.7% pre- injection to 2.9% at 24 hours post-injection, and to 3.9% at 10 days, with the magnitude of both increases being statistically significant.

Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count compared to patients treated with placebo.

Slight elevation in absolute neutrophil count and eosinophil count were observed but in a smaller proportion of patients.

The remaining 2 events (rash and eosinophil count increased, both nonserious) were possibly related to nusinersen.

Hematopoiesis Autoimmune pathologies, hemolytic anemia, increased eosinophil count, leukopenia, bone marrow suppression, reduced white blood cell count, decreased hematocrit and hemoglobin in the blood.

Moreover, SB010 significantly reduced the relative sputum eosinophil count by 58.8% (p=0.004) compared to 11% (p=0.38) in the placebo group in addition to standard therapy, including inhaled corticosteroids (ICS).

A transient increase in mean eosinophil counts was seen during the first 2 months of therapy.

Eosinophil counts declined to near baseline levels during study treatment.

The reduction rate with mepolizumab was greater in patients with higher blood eosinophil counts.

When considered alone or in combination with baseline blood eosinophils count, these factors may further identify patients who may achieve greater response from benralizumab treatment (Table 4).

Intravenous and subcutaneous administration to cynomolgus monkeys was associated with reductions in peripheral blood and bone marrow eosinophil counts, with no toxicological findings.

In clinical Studies I and II with reslizumab 3 mg/kg, decreases in blood eosinophil counts were seen following the first dose and maintained through 52 weeks of treatment with no signs of tachyphylaxis.

The effect of reslizumab in patients with asthma and elevated sputum eosinophil counts (at least 3%) was evaluated in a 15-week, phase 2, randomised, double-blind, placebo-controlled clinical study with reslizumab 3 mg/kg.

A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.

Four of these patients reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts amongst repeated exposures to the study product.

The main findings observed at the 1X dose were decreases in cortical response to ACTH stimulation, decreased absolute lymphocyte and eosinophil counts, and decreased adrenal weight.

On 28 July 2009, Glaxo Group Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Bosatria, for the treatment of adults with hypereosinophilic syndrome to reduce or eliminate the need for corticosteroid therapy and to reduce blood eosinophil counts.

Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Bosatria did not outweigh its risks in the treatment of adults with hypereosinophilic syndrome who lack the FIP1L1-PDGRF fusion gene, to reduce or eliminate the need for corticosteroid therapy and to reduce blood eosinophil counts.

Four of these patients reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product.

Common: elevated liver values (AST, ALT, alkaline phosphatase, direct and total bilirubin), increased serum creatinine, decreased haemoglobin, decreased haematocrit, blood potassium decreased, hypomagnesaemia, low albumin, decreased white blood cells, increased eosinophils, platelet count decreased, decreased neutrophils, increased urinary red blood cells, increased partial thromboplastin time, decreased total serum protein, increased urinary protein, increased prothrombin time, blood sodium decreased, increased urinary white blood cells and low calcium.

It is unknown whether the changes in WBC or eosinophil counts observed, although of no clinical significance, are due to a transient effect on WBC function.

Intravenous and subcutaneous administration to monkeys was associated with reductions in peripheral and lung eosinophil counts, with no toxicological findings.

The reduction in blood eosinophil counts by reslizumab in anti-reslizumab antibody-positive patients was not different from patients who were anti-reslizumab antibody-negative.